蛋白尿
医学
肾功能
肾脏疾病
内科学
心脏病学
疾病
心力衰竭
重症监护医学
作者
Muhammad Shahzeb Khan,Izza Shahid,Stefan D. Anker,Gregg C. Fonarow,Marat Fudim,Michael E. Hall,Adrian F. Hernandez,Alanna A. Morris,Tariq Shafi,Matthew R. Weir,Faı̈ez Zannad,George L. Bakris,Javed Butler
标识
DOI:10.1016/j.jacc.2022.10.028
摘要
Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI